bluebird bio sells itself to Carlyle, SK Capital

Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million
Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million.
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch
Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ending its tumultuous journey in the public markets as it struggled with a severe cash crunch.
Bluebird Bio to be acquired by Carlyle, SK Capital for $3.00 per share
Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital
bluebird bio plunges after take-private deal with Carlyle and SK Capital
(NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private equity firms Carlyle Group (NASDAQ:CG) and SK Capital Partners.
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners,
Bluebird Bio trading resumes
EST Bluebird Bio (BLUE) trading resumesDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving strong buy
pharmaphorum1d
Troubled gene therapy player bluebird sold for a song
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
BioPharma Dive3d
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
MedCity News4d
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity
Carlyle and SK Capital Partners have agreed to pay $3 in cash for each share of Bluebird, the biotech announced Friday. That price is a 57% discount to the company’s closing stock price Thursday ...
FiercePharma4d
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Once a darling of biotech, bluebird sells for less than $30M upfront
Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...
Business Wire11h
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed ...
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...